BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25523602)

  • 1. Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan.
    Lin SY; Chen TC; Lu PL; Lin CY; Lin WR; Yang YH; Chen YH
    BMC Infect Dis; 2014 Dec; 14():705. PubMed ID: 25523602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients.
    Hsu CS; Huang CJ; Kao JH; Lin HH; Chao YC; Fan YC; Tsai PS
    PLoS One; 2013; 8(7):e70458. PubMed ID: 23894660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan.
    Hsu CS; Kao JH; Chao YC; Lin HH; Fan YC; Huang CJ; Tsai PS
    Aliment Pharmacol Ther; 2013 Aug; 38(4):415-23. PubMed ID: 23802888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of rheumatoid arthritis in patients with hepatitis C virus infection receiving interferon-based therapy: a retrospective cohort study using the Taiwanese national claims database.
    Tung CH; Lai NS; Li CY; Tsai SJ; Chen YC; Chen YC
    BMJ Open; 2018 Jul; 8(7):e021747. PubMed ID: 30037875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Taiwanese Nationwide Cohort Study Shows Interferon-Based Therapy for Chronic Hepatitis C Reduces the Risk of Chronic Kidney Disease.
    Chen YC; Hwang SJ; Li CY; Wu CP; Lin LC
    Medicine (Baltimore); 2015 Aug; 94(32):e1334. PubMed ID: 26266379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of interferon-based therapy with risk of autoimmune diseases in patients with chronic hepatitis C virus infection: A population-based Taiwanese cohort study.
    Chou SM; Yeh HJ; Lin TM; Chang YS; Hsu HC; Shen YC; Kuo TT; Chen JH; Chen SC; Chang CC
    Front Immunol; 2022; 13():992819. PubMed ID: 36275719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.
    Chang YK; Tseng YT; Chen KH; Chen KT
    BMC Endocr Disord; 2019 Apr; 19(1):36. PubMed ID: 30953492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.
    Liu CJ; Chu YT; Shau WY; Kuo RN; Chen PJ; Lai MS
    Gut; 2014 Mar; 63(3):506-14. PubMed ID: 23676440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INCIDENCE OF TUBERCULOSIS AMONG HIV/HCV CO-INFECTED PATIENTS RECEIVING HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN GEORGIA.
    Abutidze A; Bolokadze N; Chkhartishvili N; Sharvadze L; Tsertsvadze T
    Georgian Med News; 2016 Mar; (252):10-5. PubMed ID: 27119828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.
    Hsu YC; Lin JT; Ho HJ; Kao YH; Huang YT; Hsiao NW; Wu MS; Liu YY; Wu CY
    Hepatology; 2014 Apr; 59(4):1293-302. PubMed ID: 24122848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin.
    Wu CM; Su FH; Muo CH; Huang JC; Wu MM; Yeh CC
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33799370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.
    Hsu YC; Ho HJ; Wu MS; Lin JT; Wu CY
    Hepatology; 2013 Jul; 58(1):150-7. PubMed ID: 23389758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon alpha-2b plus ribavirin for chronic hepatitis C virus mixed genotype infection.
    Lin CC; Wu CH; Chen HL; Lin IT; Wang SY; Wang TE; Wang HY; Shih SC; Bair MJ
    Ann Hepatol; 2014; 13(4):350-5. PubMed ID: 24927605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study.
    Chang SC; Hung CT; Li SF; Lee HM; Chung YC; Pai LW; Yang SS
    J Formos Med Assoc; 2015 Sep; 114(9):829-34. PubMed ID: 24090634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection.
    Su TH; Liu CJ; Tseng TC; Chou SW; Liu CH; Yang HC; Wu SJ; Chen PJ; Chen DS; Chen CL; Kao JH
    Aliment Pharmacol Ther; 2019 Feb; 49(3):331-339. PubMed ID: 30592071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Treated and Untreated Chronic Hepatitis C With the Incidence of Active Tuberculosis Disease: A Population-Based Cohort Study.
    Baliashvili D; Blumberg HM; Benkeser D; Kempker RR; Shadaker S; Averhoff F; Gvinjilia L; Adamashvili N; Magee M; Kamkamidze G; Zakalashvili M; Tsertsvadze T; Sharvadze L; Chincharauli M; Tukvadze N; Gandhi NR
    Clin Infect Dis; 2023 Jan; 76(2):245-251. PubMed ID: 36134743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan.
    Yu ML; Yeh ML; Tsai PC; Huang CI; Huang JF; Huang CF; Hsieh MH; Liang PC; Lin YH; Hsieh MY; Lin WY; Hou NJ; Lin ZY; Chen SC; Dai CY; Chuang WL; Chang WY
    Medicine (Baltimore); 2015 Apr; 94(13):e690. PubMed ID: 25837762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.